Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Comprehensive Income 2010-2025 | IRWD

Ironwood Pharmaceuticals comprehensive income from 2010 to 2025. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
  
Ironwood Pharmaceuticals Annual Comprehensive Income
(Millions of US $)
2024 $1
2023 $-3
2022 $0
2021 $0
2020 $0
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $0
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Ironwood Pharmaceuticals Quarterly Comprehensive Income
(Millions of US $)
2025-03-31 $0
2024-12-31 $1
2024-09-30 $-2
2024-06-30 $0
2024-03-31 $-1
2023-12-31 $-3
2023-09-30 $-1
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31
2009-09-30 $0
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.100B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $86.060B 32.28
Zoetis (ZTS) United States $72.110B 26.91
Daiichi Sankyo, - (DSNKY) Japan $50.342B 25.61
Takeda Pharmaceutical (TAK) Japan $45.851B 9.12
Sandoz Group AG (SDZNY) Switzerland $21.340B 0.00
Summit Therapeutics (SMMT) United States $19.139B 0.00
Merck (MKKGY) Germany $16.750B 12.27
United Therapeutics (UTHR) United States $13.925B 12.32
Shionogi (SGIOY) Japan $13.866B 13.89
Neurocrine Biosciences (NBIX) United States $11.789B 40.38
IPSEN (IPSEY) France $9.682B 0.00
Orion OYJ (ORINY) Finland $9.323B 25.21
Corcept Therapeutics (CORT) United States $8.069B 65.60
Stevanato Group S.p.A (STVN) Italy $6.847B 41.87
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.069B 0.00
Grifols, S.A (GRFS) Spain $5.586B 0.00
Ionis Pharmaceuticals (IONS) United States $5.294B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.724B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.941B 10.30
Crinetics Pharmaceuticals (CRNX) United States $2.819B 0.00
Hypermarcas (HYPMY) Brazil $2.702B 17.77
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.253B 12.19
BioCryst Pharmaceuticals (BCRX) United States $2.174B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.007B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.686B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.685B 0.00
Indivior (INDV) United States $1.546B 6.56
Evotec AG (EVO) Germany $1.431B 0.00
Guardian Pharmacy Services (GRDN) United States $1.429B 0.00
ARS Pharmaceuticals (SPRY) United States $1.426B 0.00
Dyne Therapeutics (DYN) United States $1.353B 0.00
Ocular Therapeutix (OCUL) United States $1.149B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.117B 22.35
Ardelyx (ARDX) United States $0.947B 0.00
Harrow (HROW) United States $0.944B 0.00
Collegium Pharmaceutical (COLL) United States $0.926B 4.99
Avadel Pharmaceuticals (AVDL) Ireland $0.859B 0.00
Enliven Therapeutics (ELVN) United States $0.823B 0.00
Cronos Group (CRON) Canada $0.790B 0.00
Xeris Biopharma Holdings (XERS) United States $0.763B 0.00
Akebia Therapeutics (AKBA) United States $0.743B 0.00
AleAnna (ANNA) United States $0.697B 0.00
KalVista Pharmaceuticals (KALV) United States $0.568B 0.00
USANA Health Sciences (USNA) United States $0.560B 12.17
Regulus Therapeutics (RGLS) United States $0.548B 0.00
Xencor (XNCR) United States $0.547B 0.00
Elite Pharmaceuticals (ELTP) United States $0.547B 0.00
Bioventus (BVS) United States $0.535B 13.56
Savara (SVRA) United States $0.506B 0.00
Relay Therapeutics (RLAY) United States $0.488B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.478B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.475B 0.00
Zevra Therapeutics (ZVRA) United States $0.469B 0.00
Altimmune (ALT) United States $0.468B 0.00
CytoDyn (CYDY) United States $0.424B 0.00
Oruka Therapeutics (ORKA) United States $0.419B 0.00
Siga Technologies (SIGA) United States $0.417B 8.72
Tourmaline Bio (TRML) United States $0.392B 0.00
Verve Therapeutics (VERV) United States $0.390B 0.00
Organogenesis (ORGO) United States $0.377B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.353B 9.53
Heron Therapeutics (HRTX) United States $0.285B 0.00
Nature's Sunshine Products (NATR) United States $0.265B 24.44
Aquestive Therapeutics (AQST) United States $0.227B 0.00
MediWound (MDWD) Israel $0.220B 0.00
ProKidney (PROK) United States $0.216B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.193B 0.00
Wellgistics Health (WGRX) United States $0.178B 0.00
Nanobiotix S.A (NBTX) France $0.172B 0.00
OmniAb (OABI) United States $0.172B 0.00
Avita Medical (RCEL) United States $0.169B 0.00
4D Molecular Therapeutics (FDMT) United States $0.167B 0.00
Esperion Therapeutics (ESPR) United States $0.159B 0.00
Journey Medical (DERM) United States $0.159B 0.00
Profound Medical (PROF) Canada $0.154B 0.00
Liminatus Pharma (LIMN) $0.143B 0.00
Korro Bio (KRRO) United States $0.139B 0.00
Inhibikase Therapeutics (IKT) United States $0.137B 0.00
Aclaris Therapeutics (ACRS) United States $0.136B 0.00
Aldeyra Therapeutics (ALDX) United States $0.135B 0.00
Lyell Immunopharma (LYEL) United States $0.125B 0.00
Larimar Therapeutics (LRMR) United States $0.124B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.123B 0.00
Nektar Therapeutics (NKTR) United States $0.123B 0.00
Protara Therapeutics (TARA) United States $0.122B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
VAXART, INC (VXRT) United States $0.107B 0.00
Achieve Life Sciences (ACHV) Canada $0.103B 0.00
Cassava Sciences (SAVA) United States $0.102B 0.00
Lexeo Therapeutics (LXEO) United States $0.102B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.092B 0.00
Cardiol Therapeutics (CRDL) Canada $0.088B 0.00
Fractyl Health (GUTS) United States $0.086B 0.00
Arch Biopartners (ACHFF) Canada $0.082B 0.00
Galectin Therapeutics (GALT) United States $0.081B 0.00
Champions Oncology (CSBR) United States $0.080B 13.20
Cumberland Pharmaceuticals (CPIX) United States $0.076B 56.56
Pyxis Oncology (PYXS) United States $0.074B 0.00
ESSA Pharma (EPIX) Canada $0.074B 0.00
Inotiv (NOTV) United States $0.072B 0.00
Surrozen (SRZN) United States $0.070B 0.00
Dominari Holdings (DOMH) United States $0.069B 0.00
Assertio Holdings (ASRT) United States $0.068B 0.00
Vivani Medical (VANI) United States $0.068B 0.00
Unicycive Therapeutics (UNCY) United States $0.066B 0.00
Telomir Pharmaceuticals (TELO) United States $0.065B 0.00
Nutriband (NTRB) United States $0.064B 0.00
Context Therapeutics (CNTX) United States $0.063B 0.00
Metagenomi (MGX) United States $0.062B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.057B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Prelude Therapeutics (PRLD) United States $0.051B 0.00
Century Therapeutics (IPSC) United States $0.049B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.049B 0.00
Mural Oncology (MURA) Ireland $0.047B 0.00
PMV Pharmaceuticals (PMVP) United States $0.047B 0.00
NRx Pharmaceuticals (NRXP) United States $0.047B 0.00
Avalo Therapeutics (AVTX) United States $0.042B 0.00
Karyopharm Therapeutics (KPTI) United States $0.040B 0.00
ElectroCore (ECOR) United States $0.037B 0.00
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
Acrivon Therapeutics (ACRV) United States $0.036B 0.00
Rafael Holdings (RFL) United States $0.034B 0.00
FibroGen (FGEN) United States $0.033B 0.00
SCYNEXIS (SCYX) United States $0.030B 0.00
PolyPid (PYPD) Israel $0.028B 0.00
China SXT Pharmaceuticals (SXTC) China $0.025B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Tempest Therapeutics (TPST) United States $0.023B 0.00
Enlivex Therapeutics (ENLV) Israel $0.023B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
Relmada Therapeutics (RLMD) United States $0.020B 0.00
Lipocine (LPCN) United States $0.020B 0.00
Mannatech (MTEX) United States $0.019B 0.00
BioVie (BIVI) United States $0.019B 0.00
Jupiter Neurosciences (JUNS) United States $0.019B 0.00
DURECT (DRRX) United States $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
GlycoMimetics (GLYC) United States $0.016B 0.00
VYNE Therapeutics (VYNE) United States $0.015B 0.00
MEI Pharma (MEIP) United States $0.015B 0.00
SHINECO (SISI) China $0.014B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.013B 0.00
ProPhase Labs (PRPH) United States $0.013B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
Vivos Therapeutics (VVOS) United States $0.012B 0.00
Scienture Holdings (SCNX) United States $0.012B 0.00
Talphera (TLPH) United States $0.010B 0.00
Minerva Neurosciences (NERV) United States $0.010B 1.77
Ainos (AIMD) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Biomerica (BMRA) United States $0.009B 0.00
Mangoceuticals (MGRX) United States $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Traws Pharma (TRAW) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Lyra Therapeutics (LYRA) United States $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
Aditxt (ADTX) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00